title: Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer.
abstract: Phenylketonuria (PKU) is an inborn error of metabolism caused by deficiency of the hepatic enzyme phenylalanine hydroxylase (PAH) which leads to high blood phenylalanine (Phe) levels and consequent damage of the developing brain with severe mental retardation if left untreated in early infancy. The current dietary Phe restriction treatment has certain clinical limitations. To explore a long-term nondietary restriction treatment, a somatic gene transfer approach in a PKU mouse model (C57Bl/6-Pahenu2) was employed to examine its preclinical feasibility. A recombinant adeno-associated virus (rAAV) vector containing the murine Pah-cDNA was generated, pseudotyped with capsids from AAV serotype 8, and delivered into the liver of PKU mice via single intraportal or tail vein injections. The blood Phe concentrations decreased to normal levels (< or =100 microM or 1.7 mg/dl) 2 weeks after vector application, independent of the sex of the PKU animals and the route of application. In particular, the therapeutic long-term correction in females was also dramatic, which had previously been shown to be difficult to achieve. Therapeutic ranges of Phe were accompanied by the phenotypic reversion from brown to black hair. In treated mice, PAH enzyme activity in whole liver extracts reversed to normal and neither hepatic toxicity nor immunogenicity was observed. In contrast, a lentiviral vector expressing the murine Pah-cDNA, delivered via intraportal vein injection into PKU mice, did not result in therapeutic levels of blood Phe. This study demonstrates the complete correction of hyperphenylalaninemia in both males and females with a rAAV serotype 8 vector. More importantly, the feasibility of a single intravenous injection may pave the way to develop a clinical gene therapy procedure for PKU patients.
authors.affiliation: Division of Clinical Chemistry and Biochemistry, University Children's Hospital Zürich, Zürich, Switzerland.
authors.forename: Z
authors.initials: Z
authors.lastname: Ding
authors.forename: P
authors.initials: P
authors.lastname: Georgiev
authors.forename: B
authors.initials: B
authors.lastname: Thöny
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000097:blood; D004274:DNA, Recombinant / Q000008:administration & dosage; D000229:Dependovirus / Q000235:genetics*; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage* / Q000235:genetics; D006200:Hair Color; D007275:Injections, Intravenous; D008099:Liver / Q000201:enzymology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D023421:Models, Animal; D010649:Phenylalanine / Q000097:blood; D010651:Phenylalanine Hydroxylase / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D010661:Phenylketonurias / Q000628:therapy*; D011169:Portal Vein; D012737:Sex Factors; D013623:Tail / Q000098:blood supply; D014161:Transduction, Genetic / Q000379:methods
chemical_list: D000911:Antibodies, Monoclonal; D004274:DNA, Recombinant; D010649:Phenylalanine; D010651:Phenylalanine Hydroxylase